| 12492174 |
Morpholine-3-carboxamide derivatives as prostaglandin E2 receptor 4 (EP4) agonists for the treatment of gastrointestinal and pulmonary diseases |
Benjamin Whitehurst, Miles Stuart Congreve, Giles Albert Brown |
2025-12-09 |
|
| 12391641 |
Prostaglandin EP4 receptor antagonist compounds |
Miles Stuart Congreve, Benjamin Whitehurst |
2025-08-19 |
|
| 12344621 |
CGRP antagonist compounds |
Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Elaine Cansfield, Michael Alistair O'Brien +5 more |
2025-07-01 |
|
| 12331029 |
Orexin 1 receptor antagonists |
Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Sarah Joanne Bucknell, Anne Mary Stephenson +3 more |
2025-06-17 |
|
| 12240825 |
Oxexin 1 receptor antagonists |
Giles Albert Brown, Miles Stuart Congreve, John Andrew Christopher, Sarah Joanne Bucknell, Anne Mary Stephenson +5 more |
2025-03-04 |
|
| 12234227 |
Pyrazole derivatives as H4 antagonist compounds |
Giles Albert Brown, Miles Stuart Congreve, Barry John Teobald, Charlotte Fieldhouse, Mark Pickworth +1 more |
2025-02-25 |
|
| 12227521 |
CGRP antagonist compounds |
Giles Albert Brown, Miles Stuart Congreve, Stephen Paul Watson, Julie Elaine Cansfield, Michael Alistair O'Brien +3 more |
2025-02-18 |
|
| 9145407 |
Sulfonamide compounds |
Christopher John Markworth, Brian Edward Marron, David James Rawson, Robert Ian Storer, Christopher William West +1 more |
2015-09-29 |
$193,164,000 |
| 9102621 |
Acyl sulfonamide compounds |
Alan Daniel Brown, David James Rawson, Robert Ian Storer |
2015-08-11 |
$633,506,000 |
| 9096500 |
Acyl sulfonamide compounds |
Alan Daniel Brown, David James Rawson, Robert Ian Storer |
2015-08-04 |
$291,791,000 |
| 9096558 |
N-sulfonylbenzamide compounds |
Benjamin Scott Greener, Brian Edward Marron, David S. Millan, David James Rawson, Robert Ian Storer |
2015-08-04 |
$291,791,000 |
| 9085517 |
Sulfonamide derivatives |
David James Rawson, Robert Ian Storer |
2015-07-21 |
$592,689,000 |
| 9067922 |
Chemical compounds |
Robert Ian Storer, Robert McKenzie Owen |
2015-06-30 |
$178,322,000 |
| 8907101 |
Sulfonamide derivatives |
Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David S. Millan +7 more |
2014-12-09 |
$643,454,000 |
| 8772293 |
Chemical compounds |
Alan Daniel Brown, Marcel John De Groot, Brian Edward Marron, David James Rawson, Thomas Ryckmans +3 more |
2014-07-08 |
$296,854,000 |
| 8772343 |
Chemical compounds |
Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Manuel Perez-Pacheco, David James Rawson +1 more |
2014-07-08 |
$296,854,000 |
| 8741934 |
Inhibitors of ion channels |
Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard |
2014-06-03 |
$588,652,000 |
| 8685977 |
Chemical compounds |
Andrew Simon Bell, Alan Daniel Brown, Russell Andrew Lewthwaite, Ian Roger Marsh, David S. Millan +6 more |
2014-04-01 |
$235,129,000 |
| 8592629 |
Sulfonamide derivatives as Nav 1.7 inhibitors |
Andrew Simon Bell, Alan Daniel Brown, Marcel John De Groot, Russell Andrew Lewthwaite, Ian Roger Marsh +6 more |
2013-11-26 |
$220,822,000 |
| 8541588 |
Sulfonamide derivatives |
Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David S. Millan +7 more |
2013-09-24 |
$306,953,000 |
| 8357711 |
Heterocyclic sulfonamides as inhibitors of ion channels |
Brian Edward Marron, Paul Christopher Fritch, Christopher John Markworth, Andrew Thomas Maynard |
2013-01-22 |
$619,239,000 |
| 8153814 |
Sulfonamide derivatives |
Serge Beaudoin, Michael Christopher Laufersweiler, Christopher John Markworth, Brian Edward Marron, David S. Millan +7 more |
2012-04-10 |
$582,544,000 |
| 7507742 |
Spirocyclic derivatives |
David James Rawson |
2009-03-24 |
$217,987,000 |
